Mineralys Therapeutics (MLYS) News Today $16.78 +0.61 (+3.77%) Closing price 04:00 PM EasternExtended Trading$16.77 -0.01 (-0.03%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.5% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.5% - Should You Sell?March 25 at 4:41 PM | marketbeat.comMineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 1:04 PM | insidermonkey.comMineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ETMarch 25 at 8:00 AM | globenewswire.comBuy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety ProfileMarch 20, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 7.9% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Up 7.9% - Time to Buy?March 20, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Hits New 12-Month High - Still a Buy?Mineralys Therapeutics (NASDAQ:MLYS) Sets New 12-Month High - What's Next?March 20, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume Following Insider Buying ActivityMarch 20, 2025 | americanbankingnews.comMineralys Therapeutics to Present Phase 2 Trial Data on Lorundrostat for Uncontrolled Hypertension at ACC.25March 19, 2025 | nasdaq.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Insider Buying ActivityMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume Following Insider Buying ActivityMarch 19, 2025 | marketbeat.comMineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25March 19, 2025 | msn.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Major Shareholder Purchases 600,000 Shares of StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) major shareholder Samsara Biocapital Gp, Llc bought 600,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was bought at an average price of $13.50 per share, with a total value of $8,100,000.00. Following the acquisition, the insider now owns 5,674,916 shares in the company, valued at approximately $76,611,366. This represents a 11.82 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.March 18, 2025 | marketbeat.comInsider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Buys 1,296,296 Shares of StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Ra Capital Management, L.P. purchased 1,296,296 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $17,499,996.00. Following the completion of the purchase, the director now owns 4,280,051 shares of the company's stock, valued at approximately $57,780,688.50. This trade represents a 43.45 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 18, 2025 | marketbeat.comIs Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?March 18, 2025 | insidermonkey.comMineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | markets.businessinsider.comMineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common StockMarch 18, 2025 | globenewswire.comSamsara Biocapital Gp, Llc Acquires 600,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMarch 18, 2025 | insidertrades.comMineralys Therapeutics announces data from Phase 2 Advance-HTN trialMarch 17, 2025 | markets.businessinsider.comMineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & ExpoMarch 17, 2025 | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Trading Up 3.4% - Here's What HappenedMineralys Therapeutics (NASDAQ:MLYS) Trading Up 3.4% - Here's WhyMarch 14, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What HappenedMarch 13, 2025 | marketbeat.comMineralys Reports Positive Results for Hypertension Drug LorundrostatMarch 13, 2025 | msn.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 9.5% - Should You Sell?Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 9.5% - What's Next?March 12, 2025 | marketbeat.comMineralys Therapeutics prices $175M stock offeringMarch 12, 2025 | msn.comProficio Capital Partners LLC Purchases New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Proficio Capital Partners LLC purchased a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 23,192 shares of the company's stock, vMarch 12, 2025 | marketbeat.comMineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common StockMarch 11, 2025 | globenewswire.comMineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Monday.March 11, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Reaches New 1-Year High - Should You Buy?Mineralys Therapeutics (NASDAQ:MLYS) Reaches New 1-Year High - Here's WhyMarch 11, 2025 | marketbeat.comBank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)March 11, 2025 | markets.businessinsider.comMineralys Therapeutics announces $250M common stock offeringMarch 11, 2025 | markets.businessinsider.comMineralys' drug for persistent hypertension succeeds in two trialsMarch 10, 2025 | msn.comMineralys: Prospects Just Got Better With Successful Pivotal Data ReadoutsMarch 10, 2025 | seekingalpha.comMineralys Therapeutics Announces Proposed Public Offering of Common StockMarch 10, 2025 | globenewswire.comPromising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.March 10, 2025 | tipranks.comBuy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study OutcomesMarch 10, 2025 | tipranks.comMineralys Therapeutics stock soars on positive hypertension trial resultsMarch 10, 2025 | au.investing.comMineralys Posts Positive Lorundrostat Study Results for Uncontrolled HypertensionMarch 10, 2025 | marketwatch.comMineralys Therapeutics Shares Hit 52-Week High on Hypertension Study ResultsMarch 10, 2025 | marketwatch.comMineralys Therapeutics announces results from Launch-HTN, Advance-HTN trialsMarch 10, 2025 | markets.businessinsider.comGoldman Sachs Remains a Buy on Mineralys Therapeutics, Inc. (MLYS)March 10, 2025 | markets.businessinsider.comMineralys Therapeutics' stock price explodes after lorundrostat study resultsMarch 10, 2025 | bizjournals.comMineralys Therapeutics' blood pressure drug meets goal in trialsMarch 10, 2025 | reuters.comMineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant HypertensionMarch 10, 2025 | globenewswire.comMineralys Therapeutics to Announce Pivotal Trial Results for LorundrostatMarch 9, 2025 | msn.comCandriam S.C.A. Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Candriam S.C.A. bought a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 305,272 shares of the company's stock, valued at approximatMarch 9, 2025 | marketbeat.comStocks to Watch: Cognizant Technology Solutions, Mineralys Therapeutics, PDF SolutionsMarch 7, 2025 | marketwatch.comMineralys Therapeutics Rises Ahead of Hypertension-Drug Trial DataMarch 7, 2025 | marketwatch.comMineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ETMarch 7, 2025 | globenewswire.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 6.1% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Up 6.1% - Should You Buy?March 7, 2025 | marketbeat.comBuy Rating for Mineralys Therapeutics, Inc. Driven by Lorundrostat’s Potential in Hypertension TreatmentMarch 5, 2025 | tipranks.comGuggenheim Reaffirms Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)Guggenheim reiterated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday.February 24, 2025 | marketbeat.com Remove Ads Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.740.62▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼133▲MLYS Articles Average Week Remove Ads Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RXRX News Today XENE News Today AMRX News Today CPRX News Today HCM News Today BHC News Today NAMS News Today TWST News Today EWTX News Today IBRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLYS Stock Free MLYS Stock Alerts